Pimafucort 10mg/g+3500U/g+10mg/g cream for external use

Maa: Armenia

Kieli: englanti

Lähde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Valmisteyhteenveto Valmisteyhteenveto (SPC)
06-05-2017

Aktiivinen ainesosa:

natamycin, neomycin (neomycin sulfate), hydrocortisone (hydrocortisone micronized)

Saatavilla:

Temmler Italia S.r.L.

ATC-koodi:

D07CA01

INN (Kansainvälinen yleisnimi):

natamycin, neomycin (neomycin sulfate), hydrocortisone (hydrocortisone micronized)

Annos:

10mg/g+3500U/g+10mg/g

Lääkemuoto:

cream for external use

Kpl paketissa:

aluminium or plastic tube 15g

Prescription tyyppi:

Prescription

Valtuutuksen tilan:

Registered

Valtuutus päivämäärä:

2017-05-06

Valmisteyhteenveto

                                PIMAFUCORT, cream for external use
PIMAFUCORT, ointment for external use
Summary of Product Characteristics
1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
TRADE NAME OF THE MEDICINAL PRODUCT: Pimafucort
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_CREAM: _
1 g of cream contains:
_Active ingredients:_
natamycin 10 mg
neomycin (as neomycin sulfate) 3500 Units
hydrocortisone micronised 10 mg
_Excipients:_
Sodium citrate 14.0 mg, emulsifier F 115.0 mg, sorbitan stearate 30.0
mg, cetyl esters
wax
60.0
mg,
cetiol
V
150.0,
macrogol
stearate
100
20.0
mg,
methyl
parahydroxybenzoate 2.0 mg, propyl parahydroxybenzoate 0.50 mg,
purified water up to
1000.0 mg.
_OINTMENT: _
1 g of ointment contains:
_Active ingredients:_
natamycin 10 mg
neomycin (as neomycin sulfate) 3500 Units
hydrocortisone micronised 10 mg
_Excipients:_
Polyethylene ointment base (95 % of liquid paraffin, 5 % of
polyethylene) 976.5 mg.
3.
PHARMACEUTICAL FORM:
Cream for external use.
Ointment for external use.
DESCRIPTION
Cream: White to white with yellowish shade cream.
Ointment: White to yellow ointment.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Dermatoses
susceptible
to
glucocorticosteroid
therapy,
complicated
by
secondary
bacterial and/or fungal infection (especially, caused by fungi
Candida).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The medicine should be applied to the affected areas of skin in adults
and children 2-4
times per day. Duration of treatment is determined individually,
taking into account a
nature of disease, course of treatment usually does not exceed 14
days.
The medicine is recommended in the form of cream for the therapy of
acute and sub-
PIMAFUCORT, cream for external use
PIMAFUCORT, ointment for external use
Summary of Product Characteristics
2
acute dermatoses, including such states accompanied by weeping. The
ointment is
intended for the therapy of sub-acute and chronic dermatoses,
especially at the presence
of expressed dry skin, lichenification, seborrhea or in such cases
when the occlusive
properties of ointment are necessar
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste venäjä 10-05-2017
Valmisteyhteenveto Valmisteyhteenveto venäjä 10-05-2017